Efficacy of Eribulin in Soft Tissue Sarcomas.
Details
Serval ID
serval:BIB_BAD5D07E845B
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Efficacy of Eribulin in Soft Tissue Sarcomas.
Journal
Frontiers in pharmacology
ISSN
1663-9812 (Print)
ISSN-L
1663-9812
Publication state
Published
Issued date
2022
Peer-reviewed
Oui
Volume
13
Pages
869754
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: epublish
Publication Status: epublish
Abstract
Soft tissue sarcomas are a highly heterogenous group of tumors with limited systemic therapy options. Eribulin, a synthetic analogue of halichondrin B, is a potent mitotic inhibitor. A phase 3 trial of previously treated advanced Liposarcoma and Leiomyosarcoma demonstrated superiority of eribulin to dacarbazine. Eribulin appears to be particularly effective for liposarcomas. It has also been shown to be a safe and effective treatment alternative to doxorubicin in patients where doxorubicin is contraindicated. From retrospective studies, eribulin has demonstrated efficacy in patients with angiosarcoma, pleomorphic sarcomas, synovial sarcomas, rhabdomyosarcomas, angiosarcomas, and myxofibrosarcomas. Future areas of development include liposomal eribulin, which may provide increased efficacy and lower toxicity, and delineation of biomarkers of response and resistance, allowing better selection of patients for treatment.
Keywords
STS, eribulin, eribulin and related compounds, leiomyosarcoma, liposarcoma, review, sarcoma
Pubmed
Web of science
Open Access
Yes
Create date
03/05/2022 8:13
Last modification date
23/01/2024 7:33